Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Neostigmine and Glycopyrrolate Iontophoresis for Bowel Evacuation in SCI
NCT06351995Phase 3Active, not recruiting
- Sponsor
- James J. Peters Veterans Affairs Medical Center
- Start
- Nov 2020
- Primary completion
- Oct 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of neostigmine in neurogenic bowel (NBD), constipation and fecal incontinence (FI), sponsored by James J. Peters Veterans Affairs Medical Center. Primary endpoints: Presence or absence of bowel evacuation at 2 hours, Time to bowel evacuation at 2 hours and 2 more. Started Nov 2020; status: active, not recruiting.
02
Drugs
neostigmine
03
Conditions
neurogenic bowel (NBD)constipationfecal incontinence (FI)
Beyond the preview
Go deeper on NCT06351995.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06351995.